Healthcare insights
Read our latest healthcare insights.
Healthcare and pharma insights
Insights
Healthcare and pharma insights
Read our latest healthcare and pharma insights.
Pharma and life sciences insights
Read our latest pharma and life sciences insights.
Third party risk management
In the last few weeks, we have seen both the ransomware attack on the NHS in the news, and more recently, the impact caused by a software bug in an update from a cyber security firm, causing IT outages across the globe. These two incidents, added to the traditional high risks of issues such as bribery and corruption, stress the importance of third party risk management and due diligence.
Pharma and Life Sciences - Exploring tax reliefs
Pharma and life sciences businesses, understandably, tend to focus on the science and development of ideas and the groundbreaking therapies this might lead to. However, leveraging all available resources, such as allowances and tax reliefs, is also something these companies should be considering. While leading pharmaceutical companies have large departments dedicated to this, smaller businesses in...
Private equity and deals activity in the sector
05/10/2023. Tarifa Simpson, our Healthcare & Life Sciences Co-Lead and Due Diligence Partner, gives her views on the current deals environment within the healthcare and life sciences sector.
Bringing the ‘E’ and the ’S’ together
Acting on the principles embodied in ESG (environmental, social and governance) is fraught with difficulty.
Collaborative arrangements and tax
Why companies within the Pharmaceutical and Life Sciences sector need to be aware of the tax implications before entering into collaborative arrangements.